Heart & Lung最新文献

{"title":"Tuberculosis in Morocco: Disease duration, weight loss and malnutrition","authors":"Youssef EL BAHI,&nbsp;Soukaina LOULIDI,&nbsp;Samia RKHA,&nbsp;Mohamed LOUKID","doi":"10.1016/j.hrtlng.2025.06.003","DOIUrl":"10.1016/j.hrtlng.2025.06.003","url":null,"abstract":"<div><h3>Background</h3><div>Tuberculosis remains a serious challenge in public health worldwide. Changes in patients' delays in diagnosis and illness can complicate the disease. Understanding the factors affecting the delays is crucial to the development of effective prevention and treatment strategies.</div></div><div><h3>Objectives</h3><div>The aim of our study is to analyze and identify the association between the duration of illness, weight status and changes in dietary habits of TB patients as well as addressing the importance of dietary habits in improving tuberculosis outcomes.</div></div><div><h3>Methods</h3><div>A cross-sectional study was carried out on a sample of 480 tuberculosis patients.</div></div><div><h3>Results</h3><div>The results revealed that the mean (SD) duration of the disease was 5.98 months (6.8), while the mean (SD) diagnostic duration was 3.35 months (6.01). Significant difference was observed in diagnostic duration between TB types (<strong><em>p</em> = 0.018</strong>). Mean weight loss during the disease (SD) was 7.34 kg (5.21) with a significant difference between age groups (<strong><em>p</em> &lt; 0.001</strong>) and between TB types (<strong><em>p</em> &lt; 0.001</strong>). During the disease, patients lost an average of 1.72 kg/m² of their BMI (<strong><em>p</em> &lt; 0.001</strong>). Around 84 % of patients have changed their eating habits. Weight loss and changes in dietary habits were significantly associated with increased disease duration.</div></div><div><h3>Conclusions</h3><div>Changes in eating habits, marked by weight loss and reduction in patients’ food intake significantly prolonged the disease's duration. Healthcare professionals are called to be aware of the impact of eating habits on the progression and duration of tuberculosis, and to encourage their patients to adopt healthy eating practices.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"74 ","pages":"Pages 35-41"},"PeriodicalIF":2.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144480945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical correlates and prognostic significance of cardiopulmonary recovery time after 6-minute walk test in COPD versus interstitial lung disease patients","authors":"Elif Yıldırım,&nbsp;Nisanur Tutuş,&nbsp;Yagmur Aydogdu,&nbsp;Ipek Ozmen","doi":"10.1016/j.hrtlng.2025.06.001","DOIUrl":"10.1016/j.hrtlng.2025.06.001","url":null,"abstract":"<div><h3>Background</h3><div>Cardiopulmonary recovery time after 6-min walk test (6MWT) is a novel and easily interpretable marker of clinical outcomes, which has not been studied yet in the setting of chronic obstructive pulmonary disease (COPD) versus interstitial lung disease (ILD).</div></div><div><h3>Objectives</h3><div>This study aimed to investigate clinical correlates and prognostic significance of cardiopulmonary recovery time after 6MWT in COPD versus ILD patients.</div></div><div><h3>Methods</h3><div>A total of 117 patients with COPD (<em>n</em> = 52) or ILD (<em>n</em> = 65) were evaluated in terms of pulmonary function, disease impact and 6MWT parameters including 6-min walk distance (6MWD) and cardiopulmonary recovery time. Predictors of adverse clinical outcomes (emergency admissions, hospitalizations, mortality) were also evaluated via multivariate logistic regression analysis.</div></div><div><h3>Results</h3><div>The 6MWD was significantly shorter in the COPD group than in the ILD group (median(min-max) 389.5(84.0­597.0) vs. 476.0(120.0­635.0) m, <em>p</em> &lt; 0.001). SpO2 recovery time (<em>r</em>=-0.370, <em>p</em> = 0.037) and HRR time (<em>r</em>=-0.425, <em>p</em> = 0.017) were negatively correlated with DLCO in the ILD group. Increase in SpO2 recovery time predicted increased risk of overall adverse clinical outcomes in the ILD group (OR 1.009, <em>p</em> = 0.040). HRR time had no significant role in predicting the risk of adverse clinical outcomes in COPD and ILD groups.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that SpO2 recovery time during 6MWT may be a simple and practical novel marker to determine risk for future emergency admissions, hospitalizations and mortality in ILD patients but not in COPD patients. HRR time had no significant role in predicting adverse clinical outcomes in both COPD and ILD groups.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"74 ","pages":"Pages 19-26"},"PeriodicalIF":2.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of heart failure phenotypes on prognosis of patients with hypertrophic cardiomyopathy","authors":"Xiaoli Zhao ,&nbsp;Kai Luo ,&nbsp;Huihui Ma ,&nbsp;Xinyi Yang ,&nbsp;Rong Luo ,&nbsp;Xiaoping Li","doi":"10.1016/j.hrtlng.2025.05.015","DOIUrl":"10.1016/j.hrtlng.2025.05.015","url":null,"abstract":"<div><h3>Background</h3><div>Hypertrophic cardiomyopathy (HCM) is a highly heterogeneous disease with variable timings of complication onset and progression, whether different heart failure (HF) phenotypes are associated with adverse outcomes in HCM was incompletely unknown.</div></div><div><h3>Objective</h3><div>To explore the association of different HF phenotypes with all-cause mortality, cardiovascular events, and sudden death in HCM patients.</div></div><div><h3>Methods</h3><div>This retrospective, observational cohort study included 2292 HCM patients from 13 tertiary hospitals over the period from 1996 to 2021. The patients were categorized into four groups: without HF (HCM-non-HF), HF with highly preserved ejection fraction (HCM-HFhpEF) (LVEF ≥60 %), HF with low-normal ejection fraction (HCM-HFlnEF) (LVEF 50 %–59 %) and HF with reduced ejection fraction (HCM-HFrEF) (LVEF &lt;50 %). Kaplan-Meier and Cox proportional hazards models were employed to evaluate the prognostic differences among HCM patients with different HF phenotypes.</div></div><div><h3>Results</h3><div>Overall, of 2292 patients included, the mean age was 56.95 ± 15.24 years, 38.5 % were female, with a median follow-up period of 4.5 years. All-cause death, cardiovascular events, and sudden death occurred in 19.3 %, 11.0 %, and 4.8 %, respectively. Compared with patients with HFhpEF, those with HFlnEF and HFrEF exhibited a higher risk of all-cause death [HCM-HFlnEF: adjusted hazard ratio (aHR): 1.50, 95 % confidence interval (CI): 1.16–1.95; HCM-HFrEF: aHR 2.35, 95 % CI:1.71–3.24] and cardiovascular events (HCM-HFlnEF: aHR: 1.71, 95 % CI:1.23–2.39; HCM-HFrEF: aHR 2.09, 95 % CI: 1.35–3.23), whereas there was no significant association with sudden death; those without HF did not demonstrate increased mortality risk.</div></div><div><h3>Conclusions</h3><div>Our study suggested that HCM patients with HFlnEF and HFrEF were associated with an significantly increased risk of all-cause and cardiovascular events.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"74 ","pages":"Pages 12-18"},"PeriodicalIF":2.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep duration and cardiovascular disease causal association: A two-sample Mendelian randomization study","authors":"Haixia Xu ,&nbsp;Peng Xu ,&nbsp;Mengqi Li ,&nbsp;Yinhao Jiang ,&nbsp;Jianfeng Xu ,&nbsp;Weizhong Feng ,&nbsp;Libo Jin ,&nbsp;Linqi Li ,&nbsp;Jiacheng Wu","doi":"10.1016/j.hrtlng.2025.05.016","DOIUrl":"10.1016/j.hrtlng.2025.05.016","url":null,"abstract":"<div><h3>Background</h3><div>An increasing number of studies have recently suggested a relationship between sleep duration and cardiovascular disease (CVD). However, a correlation between the two has not been studied.</div></div><div><h3>Objective</h3><div>The aim of this study was to investigate a correlation between sleep duration and CVD.</div></div><div><h3>Methods</h3><div>This study is based on summary data from genome-wide association studies (GWAS), across various races, regarding sleep duration and 12 major cardiovascular diseases. We utilized two-sample Mendelian randomization (MR), a method specifically designed to analyze correlation, to investigate whether sleep duration directly affects risk of developing CVD. Our primary analysis used the inverse variance weighting (IVW) method to examine the effect of sleep duration on multiple cardiovascular conditions. Additionally, we employed maximum likelihood, MR-Egger regression, weighted median, and weighted mode methods to ensure the robustness of our findings.</div></div><div><h3>Results</h3><div>This study revealed a correlation between over-sleeping and three cardiovascular conditions (valvular heart disease, myocardial infarction, and heart failure) with significant negative correlations (<em>P</em> &lt; 0.05). No significant correlation was found with the remaining nine cardiovascular conditions (<em>P</em> &gt; 0.05). Furthermore, we found that under-sleeping had a correlation with four cardiovascular conditions (non-ischemic cardiomyopathy, cardiac arrhythmias, valvular heart disease, and atrial fibrillation) with significant positive correlations (<em>P</em> &lt; 0.05) butnot with the remaining eight cardiovascular conditions (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>Over-sleeping was negatively correlated with several cardiovascular diseases, whereas under-sleeping was positively correlated with others, suggesting that lack of sleep may increase the risk of certain cardiovascular conditions.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"74 ","pages":"Pages 1-11"},"PeriodicalIF":2.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144242891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AAHFN Leadership message","authors":"Robin Miller DNP, MPH, ACNP","doi":"10.1016/j.hrtlng.2025.05.013","DOIUrl":"10.1016/j.hrtlng.2025.05.013","url":null,"abstract":"","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Page A1"},"PeriodicalIF":2.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 exaggerated exertional tachycardia: Relationship with pulmonary and cardiac sequelae","authors":"Giovanna Pelà ,&nbsp;Annalisa Frizzelli ,&nbsp;Roberta Pisi ,&nbsp;Luigino Calzetta ,&nbsp;Alessandra Marchese ,&nbsp;Alfredo Chetta ,&nbsp;Marina Aiello","doi":"10.1016/j.hrtlng.2025.05.017","DOIUrl":"10.1016/j.hrtlng.2025.05.017","url":null,"abstract":"<div><h3>Background</h3><div>Long-COVID patients frequently complain of an Exaggerated Exertional Tachycardia (EET) and may represent a specific phenotype of post-COVID tachycardia syndrome. So far, no studies have investigated the factors contributing to EET.</div></div><div><h3>Objectives</h3><div>To determine the predictor factors of EET, seventy-nine Long-COVID-19 patients underwent comprehensive cardiologic and respiratory evaluations at follow-up visit after a median of 23 weeks from the acute phase of the disease. <em>Methods:</em> The heart rate (HR) response to exercise was assessed by the 6-minute walk test (6MWT), stratifying patients into two groups: EET and NET (normal exertional tachycardia). <em>Results:</em> The EET group was older, had higher body mass index and systolic blood pressure, with more comorbidities and lower resting HR, when compared to the NET group. The EET group also showed higher High-Resolution computed tomography scores and D-dimer levels during the acute phase compared to NET. At follow-up visit EET patients exhibited higher left ventricular mass and reduced systolic and diastolic function in both ventricles, as assessed by Doppler tissue echocardiography (myocardial S and E’ waves). We found a significant reduction in lung diffusion capacity and in mean oxygen saturation during the 6MWT in EET patients compared to NET ones. Stepwise logistic regression analysis identified the mean oxygen saturation during the 6MWT as the predictor of abnormal HR response to exercise.</div></div><div><h3>Conclusions</h3><div>We found that the exaggerated heart response to exercise in Long COVID-19 patients is associated to an impaired pulmonary function at rest and is predicted by the oxygen exercise-induced desaturation.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 228-235"},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Procalcitonin in acute exacerbation of interstitial lung disease: A systematic review of current evidence","authors":"Narat Srivali ,&nbsp;Federica De Giacomi","doi":"10.1016/j.hrtlng.2025.05.014","DOIUrl":"10.1016/j.hrtlng.2025.05.014","url":null,"abstract":"<div><h3>Background</h3><div>Acute exacerbation of interstitial lung disease (AE-ILD) is a severe respiratory complication with overlapping clinical features that make distinguishing it from bacterial infections challenging.</div></div><div><h3>Objectives</h3><div>Evaluate procalcitonin's (PCT) diagnostic performance in differentiating AE-ILD from bacterial infections, focusing on sensitivity, specificity, and clinical applications.</div></div><div><h3>Methods</h3><div>Systematic literature review of Medline, Embase, and Cochrane Central databases through January 2025. Included clinical trials and observational studies assessing PCT levels in patients with interstitial lung disease experiencing acute respiratory decompensation, following PRISMA guidelines.</div></div><div><h3>Results</h3><div>Three studies involving 122 patients demonstrated consistent PCT diagnostic performance. Sensitivity ranged from 88.9 % to 95.5 %, specificity from 77.3 % to 100 %. Receiver operating characteristic analysis showed strong discriminatory power, with areas under the curve up to 0.85. Initial evidence suggested correlations between PCT levels and bacterial culture positivity and potential prognostic implications.</div></div><div><h3>Conclusions</h3><div>This first systematic review reveals promising diagnostic potential of PCT in AE-ILD, though current evidence is preliminary. While PCT appears effective in differentiating bacterial infections from non-infectious exacerbations, larger multicenter studies are needed to validate these findings and address identified knowledge gaps.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 221-227"},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effectiveness of SGLT2 inhibitors in type 2 diabetes patients with myocardial injury: A population-based study","authors":"Matteo Ponzoni MD ,&nbsp;Federico Rea PhD ,&nbsp;Giovanni Corrao PhD ,&nbsp;David J Barron MD ,&nbsp;Anna Cantarutti PhD ,&nbsp;Gabriella Morabito Msc","doi":"10.1016/j.hrtlng.2025.05.020","DOIUrl":"10.1016/j.hrtlng.2025.05.020","url":null,"abstract":"<div><h3>Background</h3><div>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular benefits in randomized trials. However, real-world evidence on their cardioprotective effect in high-risk populations with documented myocardial injury—such as heart failure (HF), acute coronary syndrome (ACS), myocardial revascularization, or cardiac surgery—is still limited.</div></div><div><h3>Objective</h3><div>To evaluate the impact of SGLT2 inhibitor adherence on cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) and a history of myocardial injury, in a real-world setting.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the healthcare utilization databases of the Lombardy region (Italy) to identify all patients with T2DM who were dispensed SGLT2 inhibitors between 2014–2020, and had one hospitalization for HF, myocardial revascularization, ACS or cardiac surgery in the previous 10 years. Adherence was calculated as the proportion of days covered by therapy during follow-up. Cox regression analysis was performed to estimate the hazard ratios (HR) for cardiovascular hospitalizations and death.</div></div><div><h3>Results</h3><div>Among 1789 HF, 5759 revascularization, 3986 ACS, and 4580 cardiac surgery patients, higher adherence to SGLT2i therapy was consistently associated with a lower risk of CV events or death. Adjusted HRs for high vs. very low adherence were: HF, 0.65 (95 %CI:0.52–0.82); revascularization, 0.70 (95 %CI:0.59–0.84); ACS, 0.76 (95 %CI:0.62–0.93); and cardiac surgery, 0.69 (95 %CI:0.57–0.84). A dose-response trend was observed across adherence levels.</div></div><div><h3>Conclusion</h3><div>High adherence to SGLT2 inhibitors therapy can significantly decrease the risk of cardiovascular-related hospitalization and death in patients with T2DM and several forms of myocardial injury, such as HF, ACS, myocardial revascularization, and cardiac surgery.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 236-242"},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fear of disease progression in patients after open-heart surgery: A cross-sectional study","authors":"Zilu Liang ,&nbsp;Shaoyan Lin ,&nbsp;Huimei Sun ,&nbsp;Yingying Liao ,&nbsp;Cuishan Chen ,&nbsp;Muchen Zhang ,&nbsp;Huijuan Song","doi":"10.1016/j.hrtlng.2025.05.018","DOIUrl":"10.1016/j.hrtlng.2025.05.018","url":null,"abstract":"<div><h3>Background</h3><div>Fear of disease progression (FoP) is an emerging issue in patients after open-heart surgery (OHS), but data on this phenomenon are scarce and require further investigation.</div></div><div><h3>Objectives</h3><div>This study aims to explore the current status of FoP in patients after OHS and to detect potential factors associated with FoP.</div></div><div><h3>Methods</h3><div>A cross-sectional design with convenience sampling was conducted on 210 patients who experienced OHS in the Department of Cardiovascular Surgery of a tertiary hospital in China from March 2024 to April 2025 by the demographic and clinical characteristics questionnaire, the Fear of Progression Questionnaire-Short Form, the Medical Coping Modes Questionnaire, the Social Support Rating Scale, the Brief Illness Perception Questionnaire, and the Hospital Anxiety and Depression Scale. Data were analyzed by using correlation analysis, univariate analysis, and multiple linear regression.</div></div><div><h3>Results</h3><div>The average score of FoP was 34.55 ± 6.34, with 94 patients (44.76 %) having clinically abnormal FoP levels (score ≥ 34). The results of multiple linear regression analysis showed that age, educational level, family history of CVD, number of disease episodes, postoperative complications, anxiety and depression, coping modes (confrontation and avoidance), social support, illness perception were factors influencing FoP, accounting for 75.20 % of the total variance.</div></div><div><h3>Conclusion</h3><div>FoP is a commonly observed issue among patients after OHS. It is necessary to develop specialized psychological interventions and tailored assistance based on patient-specific factors to reduce FoP.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 214-220"},"PeriodicalIF":2.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of albumin-bilirubin score with cardiovascular risk among adults in the US","authors":"Tao Tang MD ,&nbsp;Yu Feng MD ,&nbsp;Aline M. Thomas PhD ,&nbsp;Shen Li MD, PhD","doi":"10.1016/j.hrtlng.2025.05.019","DOIUrl":"10.1016/j.hrtlng.2025.05.019","url":null,"abstract":"<div><h3>Background</h3><div>Liver dysfunction plays a significant role in cardiovascular disease (CVD), yet it lacks effective and practical clinical biomarkers for CVD screening. Albumin-bilirubin (ALBI) score, a novel liver impairment biomarker, has demonstrated significant prognostic value in heart failure.</div></div><div><h3>Objective</h3><div>To evaluate the association between the ALBI score and cardiovascular risk.</div></div><div><h3>Methods</h3><div>This nationally representative study included adults 20 years or older in age from the National Health and Nutritional Examination Survey 2001–2018. ALBI score was calculated using the formula (log₁₀ bilirubin [umol/L] * 0.66 - 0.85 * albumin [g/dL]). Outcomes were CVD prevalence and mortality. Weighted multivariable regression analyses were performed to determine the associations between ALBI score and outcomes.</div></div><div><h3>Results</h3><div>Data for 43194 adults were analyzed. A total of 4923 CVD were initially identified, and 1878 CVD-related deaths occurred over an average follow-up period of 8.9 years. A per standard deviation higher ALBI score was associated with an elevated CVD prevalence (OR 1.18, 95 % CI 1.13–1.23) and mortality (HR 1.25, 95 % CI 1.17–1.33). The odds ratios for CVD prevalence comparing the second or highest tertile to the lowest tertile of ALBI scores were 1.12 (95 % CI 0.99–1.26) and 1.35 (95 % CI 1.21–1.51), respectively (<em>P</em> for trend &lt; 0.001). The corresponding hazard ratios for CVD mortality were 1.05 (95 % CI 0.88–1.26) and 1.31 (95 % CI 1.12–1.53), respectively (<em>P</em> for trend &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>A higher ALBI score was associated with an increased risk of CVD prevalence and mortality among US adults. The ALBI score of liver dysfunction may serve as an effective marker for CVD risk stratification.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 207-213"},"PeriodicalIF":2.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}